<DOC>
	<DOCNO>NCT00028613</DOCNO>
	<brief_summary>RATIONALE : Radiolabeled monoclonal antibody locate tumor cell deliver tumor-killing substance radioactive iodine without harm normal cell . PURPOSE : Phase I trial study effectiveness radiolabeled monoclonal antibody treat patient large cell lymphoma previously treat .</brief_summary>
	<brief_title>Radiolabeled Monoclonal Antibody Treating Patients With Previously Treated Large Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose iodine I 131 monoclonal antibody Lym-1 patient previously treat diffuse large cell lymphoma . - Determine safety drug patient . - Determine response patient drug . OUTLINE : This dose-escalation , multicenter study . Patients receive unlabeled monoclonal antibody Lym-1 IV 40 minute follow 15-30 minute later iodine I 131 monoclonal antibody Lym-1 IV 2 minute . Cohorts 3-6 patient receive escalate dos iodine I 131 monoclonal antibody Lym-1 maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . Patients follow weekly 8 week every 3 month 1 year . PROJECTED ACCRUAL : A total 8-36 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion Criteria Histologic diagnosis Bcell diffuse large cell lymphoma ( REAL classification system ) confirm independent central pathology reviewer . The tumor 's Bcell phenotype confirm positive L26 ( CD20 ) . Previous treatment 2 common combination chemotherapy regimen . Patients previously treat unlabeled monoclonal antibody therapy eligible . Men woman least 18 year age . Karnofsky Performance Score ( KPS ) estimate &gt; 60 time schedule therapeutic dose 131ILym1 . Life expectancy estimate least 3 month time therapeutic dose 131I Lym1 . Measurable disease demonstrable physical examination computerize tomography ( CT ) . CT scan evidence least one indicator lesion least one diameter measure &gt; 2 cm . ( The CT scan do within 2 week image study . ) Exclusion Criteria Inability unwillingness comply follow : Bone marrow biopsy Return followup visit Remaining motionless extend period time image procedure Serial blood/urine sampling ( dosimetry patient ) Pregnancy ( Women childbearing potential must practice effective method contraception . ) Presence second malignancy except basal cell skin carcinoma carcinoma insitu cervix Presence active lymphomatous meningitis CNS involvement lymphoma . HIV positive patient . Prior total body irradiation , course prior radiation &gt; 3,000 cGy deliver &gt; 20 % central marrow lumbar vertebra within 6 month screen . Serum creatinine total bilirubin &gt; 2 x upper limit normal . Aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) alkaline phosphatase &gt; 3 x upper limit normal . Significant marrow lymphoma ( defined lymphoma cell constitute great 20 % hematopoietic marrow element iliac crest biopsy ) . A prior bone marrow biopsy acceptable meet follow criterion : If prior bone marrow involvement , biopsy must perform within 45 day screen . If prior bone marrow involvement , biopsy must perform within 90 day screen WBC count &lt; 3,500/mm3 , granulocyte count &lt; 1,500/mm3 , platelet count &lt; 125,000/mm3 . Positive human antimouse antibody ( HAMA ) serum value , define &gt; 74 ng/mL screening . Patients recovered toxicity recent antilymphoma therapy . Treatment : Colony stimulate factor GCSF GMCSF within 120 hour screen laboratory assessment . Erythropoietin ( EPO ) within month screen laboratory assessment Whole blood platelet transfusion within 120 hour screen laboratory assessment History electrocardiographic ( ECG ) evidence Qwave myocardial infarction within 6 month screen congestive heart failure ( CHF ; NYHA Stage III IV ) . Known hypersensitivity iodine iodinecontaining organic substance . Patients require therapy anticoagulant antiplatelet drug discontinue study . Patients know antiplatelet antibody .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
</DOC>